{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T02:03:18Z","timestamp":1776650598379,"version":"3.51.2"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["CRG\/2023\/000570"],"award-info":[{"award-number":["CRG\/2023\/000570"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["HCP-0041"],"award-info":[{"award-number":["HCP-0041"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"CSIR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejmech.2025.117509","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T15:05:38Z","timestamp":1741878338000},"page":"117509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Development of acylhydrazone linked thiazoles as non-covalent dual inhibitors of SARS-CoV-2 proteases"],"prefix":"10.1016","volume":"290","author":[{"given":"Vidya Jyothi","family":"Alli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shubham Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mounika","family":"Darna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vavilapalli","family":"Suresh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swapnil Anil","family":"Sule","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aruna","family":"Jangam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhavita","family":"Kattula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarva Lakshmi","family":"Pusarapu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessie","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogesh","family":"Sardana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishna Prasad","family":"Gundla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amarender Goud","family":"Burra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunta","family":"Chandra Sekhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samata Sai","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bharati","family":"Reddi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathirvel","family":"Muralidharan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiran Kumar","family":"Bokara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Addlagatta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5397-8956","authenticated-orcid":false,"given":"Surender Singh","family":"Jadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117509_bib1","unstructured":"World Health Organization 2023 data. who.int, WHO Coronavirus (COVID-19) dashboard, (n.d.). https:\/\/data.who.int\/dashboards\/covid19."},{"key":"10.1016\/j.ejmech.2025.117509_bib2","unstructured":"Centers for Disease Control and Prevention, Human Coronavirus Types, (n.d.)."},{"key":"10.1016\/j.ejmech.2025.117509_bib3","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s11427-021-1964-4","article-title":"Overview of SARS-CoV-2 genome-encoded proteins","volume":"65","author":"Bai","year":"2022","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.ejmech.2025.117509_bib4","first-page":"7880","article-title":"SARS-CoV-2 vs. SARS-CoV-1 management: antibiotics and inflammasome modulators potential","volume":"24","author":"Rat","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2025.117509_bib5","doi-asserted-by":"crossref","first-page":"9376","DOI":"10.1021\/acs.jmedchem.2c00636","article-title":"Small-molecule thioesters as SARS-CoV-2 main protease inhibitors: enzyme inhibition, structure\u2013activity relationships, antiviral activity, and X-ray structure determination","volume":"65","author":"Pillaiyar","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117509_bib6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41392-020-00335-z","article-title":"SARS-CoV-2: the many pros of targeting PLpro","volume":"5","author":"McClain","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ejmech.2025.117509_bib7","doi-asserted-by":"crossref","first-page":"8686","DOI":"10.1021\/acs.jmedchem.2c00404","article-title":"Evolutionary and structural insights about potential SARS-CoV-2 evasion of nirmatrelvir","volume":"65","author":"Yang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117509_bib8","unstructured":"National Center for Biotechnology Information. PubChem Compound Summary for CID 155903259, Nirmatrelvir., (n.d.). https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Nirmatrelvir. (accessed December 22, 2023)."},{"key":"10.1016\/j.ejmech.2025.117509_bib9","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1111\/bph.15843","article-title":"Niclosamide-A promising treatment for COVID-19","volume":"179","author":"Singh","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117509_bib10","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1002\/mco2.151","article-title":"The SARS-CoV-2 main protease (M(pro)): structure, function, and emerging therapies for COVID-19","volume":"3","author":"Hu","year":"2022","journal-title":"MedComm"},{"key":"10.1016\/j.ejmech.2025.117509_bib11","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1021\/acsptsci.2c00065","article-title":"The remarkable selectivity of nirmatrelvir","volume":"5","author":"Duveau","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2025.117509_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.876212","article-title":"Inhibitors of SARS-CoV-2 PLpro","volume":"10","author":"Calleja","year":"2022","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2025.117509_bib13","first-page":"1637","article-title":"The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations","volume":"31","author":"Joyce","year":"2022","journal-title":"Med. Chem. Res. an Int. J. Rapid Commun. Des. Mech. Action Biol. Act. Agents"},{"key":"10.1016\/j.ejmech.2025.117509_bib14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/1573406415666190614101253","article-title":"Thiazole compounds as antiviral agents: an update","volume":"16","author":"Singh","year":"2020","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117509_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27072180","article-title":"Thiazole\/thiadiazole\/benzothiazole based thiazolidin-4-one derivatives as potential inhibitors of main protease of SARS-CoV-2","volume":"27","author":"Petrou","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.117509_bib16","article-title":"Synthesis and biochemical evaluation of 8H-Indeno[1,2-d]thiazole derivatives as novel SARS-CoV-2 3CL protease inhibitors","volume":"27","author":"Wu","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.117509_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202200121","article-title":"Thiazole-based SARS-CoV-2 protease (COV M(pro)) inhibitors: design, synthesis, enzyme inhibition, and molecular modeling simulations","volume":"355","author":"Elsayed","year":"2022","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.ejmech.2025.117509_bib18","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/s41467-023-36729-0","article-title":"Identification of SARS-CoV-2 M(pro) inhibitors containing P1\u2019 4-fluorobenzothiazole moiety highly active against SARS-CoV-2","volume":"14","author":"Higashi-Kuwata","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117509_bib19","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1021\/acsinfecdis.1c00629","article-title":"Drug-repurposing screening identified tropifexor as a SARS-CoV-2 papain-like protease inhibitor","volume":"8","author":"Ma","year":"2022","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.117509_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104148","article-title":"Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2","volume":"82","author":"Driouich","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejmech.2025.117509_bib21","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s13238-020-00768-w","article-title":"Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2","volume":"11","author":"Xiong","year":"2020","journal-title":"Protein Cell"},{"key":"10.1016\/j.ejmech.2025.117509_bib22","series-title":"Anti-rna Virus Drug and Application Thereof","author":"Honglin","year":"2021"},{"key":"10.1016\/j.ejmech.2025.117509_bib23","article-title":"Thiamyxins: structure and biosynthesis of myxobacterial RNA\u2010virus inhibitors","author":"Haack","year":"2022","journal-title":"Angew. Chemie Int. Ed."},{"key":"10.1016\/j.ejmech.2025.117509_bib24","series-title":"Application of Thiazole Compound in Preparation of Anti-SARS-COV-2 Novel Coronavirus Medicine","author":"Wenlong","year":"2022"},{"key":"10.1016\/j.ejmech.2025.117509_bib25","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1002\/cmdc.202100483","article-title":"Bithiazole inhibitors of phosphatidylinositol 4\u2010kinase (PI4KIII\u03b2) as broad\u2010spectrum antivirals blocking the replication of SARS\u2010CoV\u20102, zika virus, and human rhinoviruses","volume":"16","author":"Grazia Martina","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.117509_bib26","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2404175121","article-title":"Structural and virologic mechanism of the emergence of resistance to Mpro inhibitors in SARS-CoV-2","volume":"121","author":"Hattori","year":"2024","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2025.117509_bib27","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/s41467-023-36729-0","article-title":"Identification of SARS-CoV-2 Mpro inhibitors containing P1\u20194-fluorobenzothiazole moiety highly active against SARS-CoV-2","volume":"14","author":"Higashi-Kuwata","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117509_bib28","doi-asserted-by":"crossref","first-page":"13516","DOI":"10.1021\/acs.jmedchem.3c00777","article-title":"Structure\u2013activity relationship studies of SARS-CoV-2 main protease inhibitors containing 4-Fluorobenzothiazole-2-carbonyl moieties","volume":"66","author":"Tsuji","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117509_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/srep31500","article-title":"N-acylhydrazone inhibitors of influenza virus PA endonuclease with versatile metal binding modes","volume":"6","author":"Carcelli","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.117509_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.832431","article-title":"Hydrazones and thiosemicarbazones targeting protein-protein-interactions of SARS-CoV-2 papain-like protease","volume":"10","author":"Ewert","year":"2022","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2025.117509_bib31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.medj.2023.12.004","article-title":"Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19","volume":"5","author":"Mao","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.ejmech.2025.117509_bib32","doi-asserted-by":"crossref","first-page":"21035","DOI":"10.1021\/jacs.2c04626","article-title":"Dual inhibitors of main protease (MPro) and cathepsin L as potent antivirals against SARS-CoV2","volume":"144","author":"Mondal","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.117509_bib33","first-page":"359","article-title":"Dual inhibition of COVID-19 spike glycoprotein and main protease 3CLpro by Withanone from Withania somnifera, Chinese Herb","volume":"13","author":"Patil","year":"2021","journal-title":"Med."},{"key":"10.1016\/j.ejmech.2025.117509_bib34","first-page":"2002","article-title":"Dual inhibition of cathepsin L and 3CL-pro by GC-376 constrains SARS Cov2 infection including omicron variant","author":"Kumar","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.ejmech.2025.117509_bib35","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41467-020-20718-8","article-title":"The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery","volume":"12","author":"Fu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117509_bib36","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020106275","article-title":"Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2","volume":"39","author":"Klemm","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2025.117509_bib37","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41467-021-21060-3","article-title":"Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors","volume":"12","author":"Osipiuk","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117509_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.124772","article-title":"Development of 2-chloroquinoline based heterocyclic frameworks as dual inhibitors of SARS-CoV-2 MPro and PLPro","author":"Kattula","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejmech.2025.117509_bib39","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.ejmech.2008.04.002","article-title":"A class of potent tyrosinase inhibitors: alkylidenethiosemicarbazide compounds","volume":"44","author":"Liu","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117509_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodchem.2023.135745","article-title":"Synthesis and evaluation of the antioxidant and anti-tyrosinase activities of thiazolyl hydrazone derivatives and their application in the anti-browning of fresh-cut potato","volume":"414","author":"Djafarou","year":"2023","journal-title":"Food Chem."},{"key":"10.1016\/j.ejmech.2025.117509_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114097","article-title":"Synthesis of novel thiazolyl hydrazone derivatives as potent dual monoamine oxidase-aromatase inhibitors","volume":"229","author":"Evren","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117509_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112218","article-title":"Structure-activity relationships of triazole-benzodioxine inhibitors of cathepsin X","volume":"193","author":"Fonovi\u0107","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117509_bib43","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3987\/COM-19-S(F)5","article-title":"Synthesis of 1,3,4-OXADIAZOLES as selective t-type calcium channel inhibitors","volume":"101","author":"Zhang","year":"2020","journal-title":"Heterocycles"},{"key":"10.1016\/j.ejmech.2025.117509_bib44","doi-asserted-by":"crossref","first-page":"10016","DOI":"10.1021\/bi700878g","article-title":"Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of \u03c4 aggregation and toxicity in vitro and in cells","volume":"46","author":"Pickhardt","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2025.117509_bib45","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1134\/S1068162022060085","article-title":"Synthesis and biological activity of N-acylhydrazones","volume":"48","author":"Belyaeva","year":"2022","journal-title":"Russ. J. Bioorganic Chem."},{"key":"10.1016\/j.ejmech.2025.117509_bib46","doi-asserted-by":"crossref","first-page":"14702","DOI":"10.1021\/acs.jmedchem.1c01214","article-title":"Indole chloropyridinyl ester-derived SARS-CoV-2 3CLpro inhibitors: enzyme inhibition, antiviral efficacy, structure\u2013activity relationship, and X-ray structural studies","volume":"64","author":"Ghosh","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117509_bib47","doi-asserted-by":"crossref","first-page":"8475","DOI":"10.1021\/jacs.5b03084","article-title":"Phenyl esters are potent inhibitors of caseinolytic protease P and reveal a stereogenic switch for deoligomerization","volume":"137","author":"Hackl","year":"2015","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.117509_bib48","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/14756360701425014","article-title":"The role of fluorine in medicinal chemistry","volume":"22","author":"Shah","year":"2007","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117509_bib49","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/cbic.200301023","article-title":"Fluorine in medicinal chemistry","volume":"5","author":"B\u00f6hm","year":"2004","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2025.117509_bib50","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.apsb.2020.08.014","article-title":"Crystal structure of SARS-CoV-2 papain-like protease","volume":"11","author":"Gao","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.117509_bib51","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41467-021-20900-6","article-title":"A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication","volume":"12","author":"Hattori","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117509_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.123540","article-title":"Repurposing of US-FDA approved drugs against SARS-CoV-2 main protease (M(pro)) by using STD-NMR spectroscopy, in silico studies and antiviral assays","volume":"234","author":"Khan","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejmech.2025.117509_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2015.02.059","article-title":"Design, synthesis, optimization and antiviral activity of a class of hybrid dengue virus e protein inhibitors","volume":"25","author":"Jadav","year":"2015","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117509_bib54","first-page":"281","article-title":"Synthesis of some novel 3-(2-chloro-3-quinolyl)-5-phenyl [1, 3] thiazolo [2, 3-c][1, 2, 4] triazoles, Heterocycl","volume":"9","author":"Dubey","year":"2003","journal-title":"Commun. Now."},{"key":"10.1016\/j.ejmech.2025.117509_bib55","first-page":"485","article-title":"Heterocyclic system containing bridgehead nitrogen atom: xviii. Reaction of 5-mercapto-s-triazoles with alpha-haloketones and with alkyl halides","volume":"12","author":"Dhaka","year":"1974","journal-title":"Indian J. Chem."},{"key":"10.1016\/j.ejmech.2025.117509_bib56","first-page":"403","article-title":"Condensed heterocyclic systems containing bridgehead nitrogen atom: synthesis and antimic:robial activity of s-triazolo[3, 4-b][ 1, 3, 4] thiadiazines, thiazolo[3, 2-b] -s-triazoles and isomeric thiazolo[2, 3-c ]-s-triazoles","volume":"41B","author":"Mohan","year":"2002","journal-title":"Indian J. Chcmistry"},{"key":"10.1016\/j.ejmech.2025.117509_bib57","first-page":"241","article-title":"Heterocyclic systems containing bridgehead nitrogen atom. Synthesis and bioactivity of thiazolo[3,2-b]-s-triazoles and isomeric thiazolo[2,3-c]-s-triazoles","volume":"15","author":"Mohan","year":"2006","journal-title":"Indian J. Heterocycl. Chem."},{"key":"10.1016\/j.ejmech.2025.117509_bib58","first-page":"249","article-title":"Heterocyclic systems containing bridgehead nitrogen atoms. Part XLV. Reaction of 5-mercapto-3-p-tolyl-s-triazole with \u03b1,\u03b2-bifunctional compounds","volume":"22B","author":"Jain","year":"1983","journal-title":"Indian J. Chem. Sect. B Org. Chem. Incl. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117509_bib59","first-page":"1221","article-title":"Heterocyclic systems containing a bridgehead nitrogen atom. Part XLVIII. Syntheses of thiazolo[3,2-b]-s-triazoles and thiazolo[2,3-c]-s-triazoles, Indian J. Chem. Sect. B Org. Chem. Incl","volume":"24B","author":"Narayan","year":"1985","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117509_bib60","first-page":"547","article-title":"Heterocyclic systems containing bridgehead nitrogen atoms: synthesis of s-triazolo[3,4-b][1,3,4]thiadiazines, thiazolo[3,2-b]-s-triazoles and isomeric thiazolo[2,3-c]-s-triazoles, Pol","volume":"61","author":"Mohan","year":"1987","journal-title":"J. Chem."},{"key":"10.1016\/j.ejmech.2025.117509_bib61","first-page":"268","article-title":"Bridgehead nitrogen heterocyclic systems. Synthesis and antimicrobial activity of s-triazolo[3,4-b][1,3,4]thiadiazines, thiazolo[3,2-b]-s-triazoles and isomeric thiazolo[2,3-c]-s-triazoles","volume":"69","author":"Mohan","year":"1992","journal-title":"J. Indian Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.117509_bib62","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.117509_bib63","series-title":"Test No. 425: Acute Oral Toxicity: Up-And-Down Procedure","year":"2022"},{"key":"10.1016\/j.ejmech.2025.117509_bib64","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1080\/17435390.2023.2291788","article-title":"Toxicity study of pro-angiogenic casein manganese oxide nanoparticles: an in vitro and in vivo approach","volume":"17","author":"Haque","year":"2023","journal-title":"Nanotoxicology"},{"key":"10.1016\/j.ejmech.2025.117509_bib65","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12944-019-1051-2","article-title":"Effect of Acacia hydaspica R. Parker extract on lipid peroxidation, antioxidant status, liver function test and histopathology in doxorubicin treated rats","volume":"18","author":"Afsar","year":"2019","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.ejmech.2025.117509_bib66","series-title":"Schr\u00f6dinger Release 2024-1","year":"2024"},{"key":"10.1016\/j.ejmech.2025.117509_bib67","series-title":"Proc. 2006 ACM\/IEEE Conf. Supercomput.","first-page":"84","article-title":"Scalable algorithms for molecular dynamics simulations on commodity clusters","author":"Bowers","year":"2006"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425002740?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425002740?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T14:06:34Z","timestamp":1762265194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425002740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":67,"alternative-id":["S0223523425002740"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117509","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of acylhydrazone linked thiazoles as non-covalent dual inhibitors of SARS-CoV-2 proteases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117509","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117509"}}